COVID-19 Update from the Investment Division: Russia to the Rescue?

COVID-19 Update from the Investment Division: Russia to the Rescue?
COVID-19 Update from the Investment Division: Russia to the Rescue?
(c) unsplash
Share post:

Researchers from Moscow-based Gamaleya institute, an offshoot of the Russian Ministry of Health, published detailed phase 1/2 results of their COVID-19 vaccine in the Lancet. If true (remember that we are talking about Russia), these results imply that their vaccine is both effective and has a tolerable safety profile which would make it a strong contender in the international race to defeat COVID-19.

While some moral and medical conventions were certainly skipped to get the vaccine across the finish line as first, there is no reason to believe that it could not become a viable tool to end the pandemic upon completion of ongoing phase 3 trials.

As mentioned previously, the vaccine Gam-COVID-Vac (aka Sputnik) uses a combination of two human adenoviruses rAd26-S and rAd5-S administered 21 days apart as vectors to train the immune system to detect and neutralize SARS-CoV-2. Trial results indicate that this method is effective at eliciting an immune response comparable to convalescent plasma and similar to what the other current frontrunner vaccines achieve. Interestingly and unlike its competitors, the study also describes encouraging data on CD4 and CD8 antibody responses, which are widely believed to be the key building lasting immunity.

While the safety profile is comparable to other vaccine candidates with mild to moderate side effects such as headache, fever and fatigue, the trial was conducted on only 76 relatively young (mean ~ 27 years) and based on the average weights rather skinny participants. As mentioned previously, the real challenge with vaccine trials lies in identifying and mitigating adverse side effects that affect only a small portion of the population.

Severe side effects that manifest in fewer than 0.1% of patients could still proof disastrous if entire countries are vaccinated. Also, it seems the Russian vaccine still needs to be tested on older populations as they are among the first in line to be vaccinated. Furthermore, the large scale correct administration of a vaccine with two different vectors remains an administrative and logistical challenge compared to vaccines with two identical shots.

 

Addendum: Meanwhile a group of researchers have published an open letter to the authors of the Gamelaya Institute study and the editor of the Lancet. They lament the unavailability of the data of study for peer review and highlight problematic similarities in unrelated data points in the study, suggesting that some data was either processed erroneously or manipulated outright.

 

Legal note:
Prognoses are no reliable indicator for future performance.

DOSSIER

RESPOND TO THE ARTICLE

Leave a comment Required fields are marked with *

Your email address will not be published. Required fields are marked *

Legal disclaimer

This document is an advertisement. Unless indicated otherwise, source: Erste Asset Management GmbH. Our languages of communication are German and English.

The prospectus for UCITS (including any amendments) is published in Amtsblatt zur Wiener Zeitung in accordance with the provisions of the InvFG 2011 in the currently amended version. Information for Investors pursuant to § 21 AIFMG is prepared for the alternative investment funds (AIF) administered by Erste Asset Management GmbH pursuant to the provisions of the AIFMG in connection with the InvFG 2011. The fund prospectus, Information for Investors pursuant to § 21 AIFMG, and the key investor document/KID can be viewed in their latest versions at the web site www.erste-am.com or obtained in their latest versions free of charge from the domicile of the management company and the domicile of the custodian bank. The exact date of the most recent publication of the fund prospectus, the languages in which the key investor document is available, and any additional locations where the documents can be obtained can be viewed on the web site www.erste-am.com.

This document serves as additional information for our investors and is based on the knowledge of the staff responsible for preparing it at the time of preparation. Our analyses and conclusions are general in nature and do not take into account the individual needs of our investors in terms of earnings, taxation, and risk appetite. Past performance is not a reliable indicator of the future performance of a fund.